Abstract. The objective of this article is to discuss the similarities and differences among bioequivalence approaches used by international regulatory authorities when reviewing applications for marketing new generic drug products which are systemically active and intended for oral administration. We focused on the 13 jurisdictions and organizations participating in the International Generic Drug Regulators Pilot. These are Australia, Brazil, Canada, China, Chinese Taipei, the European Medicines Association, Japan, Mexico, Singapore, South Korea, Switzerland, the USA, and the World Health Organization. We began with a comparison of how the various jurisdictions and organizations define a generic product and its corresponding reference product. We then compared the following bioequivalence approaches: recommended bioequivalence study designs, method of pharmacokinetic calculations and bioequivalence acceptance limits, recommendations for modifying bioequivalence study designs and limits for highly variable drugs and narrow therapeutic index drugs, provisions for waiving bioequivalence study requirements (granting biowaivers), and implementation of the Biopharmaceutics Classification System. We observed that, overall, there are more similarities than differences in bioequivalence approaches among the regulatory authorities surveyed.
INTRODUCTION
Generic drugs are important options that allow greater access to health care. Generic drugs are copies of innovator (reference) drugs and are the same as those innovator drugs with respect to safety, strength, route of administration, quality, performance characteristics, and intended use (1) . Throughout the world, an application for marketing approval of a new generic product must reference a corresponding product, which was approved on the basis of clinical trials to support claims of safety and efficacy. Various countries throughout the world, as well as organizations such as the Association of Southeast Asian Nations (ASEAN), European Union, and World Health Organization (WHO), have their own individual regulatory authorities and regulatory guidance for marketing approval of generic drug products (2) .Within a jurisdiction, generic drugs are generally multisource drug products, defined as products marketed by more than one manufacturer and containing the same active pharmaceutical ingredient in the same dosage form intended to be administered by the same route of administration (3) . Drug products that contain the same active ingredient(s) have the same dosage form and route of administration and are identical in strength or concentration are designated pharmaceutical equivalents (4) . Drug products that contain the same therapeutic moiety, but which are different salts, esters, or complexes of that moiety, are designated as pharmaceutical alternatives.
The establishment of bioequivalence (BE) is fundamental in successful applications for generic drug products (5) . BE is established in order to demonstrate therapeutic equivalence between the generic (test) drug product and corresponding reference drug product. Therapeutically equivalent drug products can be substituted with the full expectation that the substituted (generic or test) product will produce the same safety effect and safety profile as the originally prescribed (reference) product. Establishment of BE allows bridging of preclinical and clinical data associated with the reference product to the generic product.
Bioavailability (BA) is defined as the rate and extent to which an active ingredient or active moiety is absorbed and becomes available at the site of action. BE drug products are pharmaceutical equivalents or pharmaceutical alternatives that display comparable bioavailability when studied under similar experimental conditions. Two products are considered bioequivalent when the rate and extent of absorption of the test drug do not show a significant difference from the rate and extent of absorption of the reference drug when administered at the same molar dose of the therapeutic ingredient under similar experimental conditions (6) .
Drug rate and extent of absorption are typically assessed by conducting in vivo studies in human subjects in which generic and reference drug plasma pharmacokinetic (PK) profiles are characterized and compared. As per the different regulatory authorities, BE can be established by PK, pharmacodynamic, clinical, or in vitro endpoint studies, in general descending order of preference (7) . Pharmacodynamic, clinical, and/or in vitro endpoint studies are generally used for locally active drugs for which PK studies may not be adequate to establish BE (8) . Although "in vitro" is ranked below "clinical" in FDA's regulations, there are situations in which an in vitro approach is equally (or more) sensitive, accurate, and reproducible than conducting an in vivo study with clinical endpoints for establishing BE between two products (9) . Finally, for generic products for which BE to the corresponding reference products is self-evident, a regulatory agency may waive the requirement for conducting a BE study (10) . This is commonly referred to as granting a "biowaiver."
Since most generic drug marketing applications are for drugs intended to be systemically available, this review will emphasize comparisons of regulatory considerations governing BE studies with PK endpoints. In a BE study with PK endpoints, the PK data are used to obtain peak drug plasma concentration (C max ) as the BE measure of rate of absorption and area under the drug plasma concentration versus time profile [area under curve (AUC)] as the BE measure of extent of absorption. The time to peak drug plasma concentration, T max , is also an indicator of drug rate of absorption. It is a common practice to log-transform generic and reference AUC and C max values and compare the geometric mean ratios (GMRs). Two products are deemed bioequivalent if these generic/reference GMRs fall within specified BE limits.
The BA/BE concept is pivotal to generic drug development throughout the world. Currently available approaches to determine BE of generic products are largely standardized, although there are still differences that can potentially lead to barriers in international data exchange. The objective of the following article is to survey international approaches for demonstrating BE of generic drug products, with an emphasis on ways in which the approaches are similar versus ways in which the approaches differ. Identification of such similarities and differences is a preliminary step for exploring ways to promote collaboration and convergence among regulatory health authorities who are faced with making decisions about the BE of generic drugs relative to corresponding reference products.
It is important to note that BE documentation has a pivotal role in new drug development as well. BE studies are used to establish links among (1) early and late clinical efficacy trial formulations, (2) formulations used in clinical trial and stability studies, if different, and (3) clinical trial formulations and to-be-marketed formulations (11) . BE studies may be necessary to support some types of postapproval manufacturing, site, or formulation changes. Although the focus of this article is on generic drug development, all of the approaches discussed herein also apply to BE studies in the context of new drug development.
METHODS
The objective of this review is to compare across various international jurisdictions and organizations the regulatory approaches for establishing BE of generic drugs to their corresponding reference drugs. The jurisdictions and organizations to be discussed will be those currently participating in the International Generic Drug Regulators Pilot (12, 13) . Table I Table II shows how the different jurisdictions and organizations define a generic drug product. Australia, Brazil, Chinese Taipei, Japan, Switzerland, and the USA stipulate that a generic drug product must be pharmaceutically equivalent to the corresponding reference drug product. The above jurisdictions define pharmaceutical equivalents as containing identical amounts of the same active drug substance in the same dosage form and route of administration (4) . Canada defines pharmaceutical equivalents as comparable dosage forms instead of as the same dosage form. Specifically, Section C.08.001.1 of the Canadian Food and Drug Regulations states that pharmaceutical equivalent means "a new drug that, in comparison with another drug, contains identical amounts of the identical medicinal ingredients, in comparable dosage forms, but that does not necessarily contain the same non-medicinal ingredients." This means that, for example, a generic tablet could be compared to a reference that is a capsule.
RESULTS

Definitions of a Generic Drug Product and Reference Drug Product
In China, Singapore, and the ASEAN, generic drugs can be pharmaceutical alternatives to the reference drug product. Pharmaceutical alternatives must be of the same strength and route of administration; an example of suitable pharmaceutical alternatives is a capsule and a tablet containing the same active drug substance in the same strength. Similarly, South Korea and the WHO define a generic drug product as a pharmaceutical product that is interchangeable with the innovator. In the EMA, a generic should contain the same active substance and be in the same dosage form as the reference product. "Same active substance" is defined as a different salt, ester, ether, isomer, mixture of isomers, complexes, or derivatives of an active substance, unless differing significantly in properties of safety and efficacy. All jurisdictions emphasize that the approved generic drug product must meet quality specifications set by the regulatory agency granting the approval.
Table II also shows how the different jurisdictions and organizations define a suitable reference drug product. In general, the reference or innovator drug product must be approved and in the jurisdiction in which the generic drug applicant seeks marketing authorization. Generally, the preferred reference product is the one sold domestically, although only Brazil formally states this as an additional requirement. In Australia, Canada, and Switzerland, it is possible in limited situations to use a reference product, which is approved and marketed outside of the country, provided that certain rigorous criteria are met. Mexico formerly required pharmaceutical manufacturers to have production facilities in the country (36) . In 2008, the Mexican government abolished the legislation The proposed generic drug product must be a pharmaceutical equivalent of the reference product (21) The TGA prefers that the proposed generic product reference a leading brand product purchased within Australia. When justified by appropriate in vitro comparative studies, the TGA will accept BE studies where the innovator drug product was sourced from outside of Australia, although this approach is not permitted for certain types of drug substances, such as NTI drugs, drugs with complex or nonlinear kinetics, and HV drugs (14, 22) Brazil A drug product that contains the same active drug substance, same pharmaceutical dosage form, same route of administration, dosing, and therapeutic indication as the reference product (23) The reference product must be registered at ANVISA, supported by documentation related to its safety, efficacy, and quality, and it must be sold in the Brazilian market
Canada
The proposed generic drug product must be a pharmaceutical equivalent of the reference product (24) (A) A drug product in respect of which a notice of compliance is issue in pursuant with Canadian regulations and which is marketed in Canada by the innovator of the drug (B) A drug product, acceptable to the Minister (of Health), that can be used for the purposes of demonstrating BE on the basis of pharmaceutical and. Where applicable, bioavailability characteristic, where a drug in respect of which a notice of compliance has been issued in pursuant with the Canadian regulations cannot be used for that purpose because it is no longer marketed in Canada (C) A drug product, that is acceptable to the Minister (of Health) that can be used for the purpose of demonstrating bioequivalence on the basis of the pharmaceutical and. Where applicable, bioavailability, characteristics, in comparison to a drug referred according to their regulations (25) China Essentially similar products, defined as either pharmaceutical equivalents or pharmaceutical alternatives (26) The corresponding innovator's drug product or the major market corresponding drug product Chinese Taipei A product that contains the same active ingredients(s) and is comparable to an approved innovator's medicinal product in dosage form, strength, route of administration, quality characteristics, and intended use (27) Generally the innovator drug product marketed in Chinese Taipei, or the first approval drug product in Chinese Taipei EMA A drug product that has the same qualitatively (Q1) and quantitatively (Q2) composition in active substances, having the same pharmaceutical form as the reference product A drug product whose marketing authorization in the EU has been granted on the basis of a complete dossier Different salts, esters, ethers, isomers, mixtures of isomers, complexes or derivatives of an active substance are considered the same active substance, unless they differ significantly in properties in regards to safety and/or efficacy (3) If there are several dosage forms of this medicinal product on the market, the reference should be the dosage form used for the initial approval of the concerned medicinal product and which was used in the clinical efficacy and safety studies (if available) Japan The proposed generic product must be a pharmaceutical equivalent of the reference product (28) . A drug product that has been approved as a new drug, or a drug that corresponds to one (29) .
Mexico
The formulation must be pharmaceutically equivalent to that of the reference product (30) A drug product that was registered with the Ministry of Health, which is available commercially and that is selected pursuant to the criteria established in the official regulations (31) Singapore / ASEAN Essentially similar products, defined as either pharmaceutical equivalents or pharmaceutical alternatives (32) An innovator drug product, which is a drug product that is authorized and marketed on the basis of a full dossier, i.e., including chemical, biological, pharmaceutical, pharmacological-toxicological and clinical data South Korea A drug product whose active ingredient and route of administration is the same as those of the reference product (33) A drug that is approved (or an approved imported drug product) the safety and efficacy of which has been established or recognized by the Commissioner of the Korea FDA Switzerland A substitutable generic drug formulation must be pharmaceutically equivalent to that of the reference product (20) The original product which is authorized in Switzerland, or Different salts, esters, ethers, isomers, mixtures of isomers, complexes or derivatives of an active substance are considered the same active substance, unless they differ significantly in properties in regards to safety and/or efficacy A product registered outside of Switzerland, provided that it meets criteria for proving comparability to the original Swiss product (34) USA The formulation must be pharmaceutically equivalent to that of the reference product (4) A reference listed drug means the listed drug identified by the FDA as the drug product upon which an applicant relies in seeking approval of its ANDA WHO A pharmaceutical product that is interchangeable with the innovator, which is usually marketed with license from the innovator company and marketed after expiry of the patent or other exclusivity rights (35) A drug product that is usually the first authorized for marketing (normally as a patented product) on the basis of documentation of efficacy, safety and quality (according to the requirements at the time of authorization) requiring companies to have a plant in Mexico if they wished to distribute their products (37). The WHO Prequalification of Medicines Programme (PQP) defines the reference product as one that is usually the first authorized for marketing, normally a patented product, on the basis of documentation of safety, efficacy, and quality, as per the requirements in effect at the time of authorization. The PQP places further stipulations on what would be considered an acceptable reference product. The primary stipulation is that comparator products should be purchased from a well-regulated market with stringent regulatory authority, that is, from countries participating in the International Conference on Harmonization. This is an important point because unlike national regulatory agencies, the WHO is not tied to any specific national market, and the use of an innovative product from "anywhere" as a reference could be problematic.
General BE Study Design
All require that a proposed generic drug product demonstrate that it is bioequivalent to the corresponding reference product. Table III shows similarities and differences in BE study design recommendations across these jurisdictions and organizations. Most often, the recommended BE study design is a randomized, single-dose, two-way crossover in healthy normal subjects. Patients should be used for reasons of safety only. Japan recommends using achlorhydric subjects in BE studies in some cases. Most of the jurisdictions and organizations recommend that a BE study enroll at least 12 subjects; a few suggest 18 or 24. With respect to subject demographics, all recommend age range and body weight restrictions. Most recommend that both male and female subjects be enrolled.
All recommend that generally the highest dose strength be used for in vivo BE studies, unless reasons of safety justify using a lower strength. In the case of drug substances that are characterized by nonlinear PK over the clinical dosing range, Canada, the EMA, USA, and WHO specify which dose strength should be used in these cases, depending on the type of nonlinearity and the underlying mechanism. All ask that the parent drug be measured in the appropriate biological fluid and subjected to BE statistics, unless the parent cannot be measured accurately and reproducibly. This is the case even for prodrugs. However, the jurisdictions and organizations differ in recommending other situations where it is necessary to measure metabolites in a BE study and what type of statistical evaluation should be performed on such metabolites. There is very little common ground regarding the metabolite measurement issue.
Australia, Canada, the EMA, and USA will accept a two-stage group-sequential BE study design in limited circumstances, provided that (1) a desirable overall type I error rate is maintained and (2) the analysis of the first stage is treated as an interim analysis and both analyses are conducted at adjusted significance levels. In addition, Canada and the USA will accept a two-stage adaptive BE study design, and Japan and South Korea will accept add-on studies. All state that the proposal and specifics of using a groupsequential, adaptive, or add-on study must be specified a priori in the study protocol. Table IV shows similarities and differences in BE study type for various dosage forms. All jurisdictions and organizations request at least a single-dose, fasting BE study for immediate-release (IR) solid oral dosage forms. The USA is the only jurisdiction that requests a single-dose fed BE study routinely for IR oral products, with few exceptions (45) . Brazil, Canada, the EMA, and Singapore/ASEAN request a fed BE study for IR oral products under certain circumstances. All request that a fed BE study be conducted for modified-release (MR) oral dosage forms. Most emphasize that the drug product should be given no later than 30 min following meal consumption. Some specify meal composition in their respective BE guidelines. Canada, the EMA, Chinese Taipei, South Korea, and the USA (46) recommend that, in the fed BE study, the drug product be administered with a high-fat meal that is high in kilocalories. The WHO recommends that the meal be based on local custom and diet.
BE Study Design Types Recommended for Various Solid Dosage Forms
At present, only two jurisdictions provide guidance on whether BE should be established for alternative modes of administration for MR oral formulations, specifically for sprinkling on soft food. These are Canada and the USA. Canada recommends that the applicant contact Health Canada prior to commencement to verify the most appropriate mode of drug administration prior to the biostudy (25) . Data should be provided to demonstrate that the technology used in the formulation is robust and that the controlled-release properties, if any, are not altered during the proposed period of time by exposure to the foods specified in the labeling. The USA recommends that, when the labeling for the RLD for a MR drug product indicates that the product may be sprinkled on soft foods, an in vivo sprinkle BE study comparing the test and RLD products should be performed (47). Both products should be sprinkled on one of the soft foods listed in the labeling (e.g., applesauce). The BE data should be analyzed using the average BE approach; acceptance criteria are that the 90% confidence intervals (CIs) of the test/reference GMRs for AUC and C max should fall within 80-125% limits.
The jurisdictions and organizations request multiple-dose BE studies under varying circumstances. All recommend that this study design may be necessary when the BE study must be conducted in patients for which the drug product is indicated, for safety reasons. China, Chinese Taipei, the EMA, South Korea, and the WHO recommend multiple-dose BE studies in some or all circumstances (depending on the jurisdiction/organization) for MR oral drug products. The EMA publishes a guideline on developing generic transdermal dosage forms, and requests both single-and multipledose BE studies for generic versions of these formulations (48) . Brazil, Japan, and the WHO organization recommend that multiple-dose BE studies be used when drug PK is highly variable or where assay sensitivity is too low to accurately characterize a PK profile following single dose administration. Chinese Taipei, Singapore/ASAEN, and the WHO also recommend use of multiple-dose BE studies for drugs that exhibit nonlinear PK.
Calculating PK Parameters and BE Statistics
Table V presents similarities and differences in determining PK parameters and BE statistics. The basic PK Number of units of test product to be manufactured for the bioequivalence study Similarities Most specify a minimum test product batch size Differences Australia, Canada, Chinese Taipei, EMA, USA, Switzerland, WHO: a minimum of 10% of the commercial batch size or 100,000 units, whichever is greater Brazil, Singapore/ASEAN: Not specified China: a scaled-up batch or a full production batch Japan: It is recommended to use a lot manufactured at the same lot size as the full-scale production. However, a lot manufacture at a scale of not less than 1/10 of a full-scale production also can be used. South Korea: At least 100,000 units Basic study design Similarities All recommend the following BE study designs The standard study design is a two-period crossover, in which each subject is given the test and reference formulations; Replicated crossover designs may also be used; and Parallel designs may be used for long half-life drugs Differences None in this regard Subjects Similarities All request healthy normal subjects, unless, for reasons of safety, it becomes necessary to use patients Differences Japan: subjects with low gastric acidity (achlorhydric subjects) should be employed in cases where (1) the use of the drug is not limited to a specific population; and (2) China: within the normal range according to accepted normal values for BMI; avoid high variances in subjects' body weights Chinese Taipei: consideration of demographic attributes of a healthy normal adult population Japan: Not specified Mexico: body weight should be no different than ±10% of the weight South Korea: a medical doctor should consider the age and health condition of the subjects USA: individuals representative of the general population WHO: weight within an acceptable range according to accepted life tables Gender, ethnicity Similarities Any females used in the bioequivalence studies should not be pregnant Differences Brazil: depending on the drug product, the same number of males and females, to be distributed equally between the sequences China: in general, it is recommended to recruit healthy male subjects. The study population should be determined based on the specific situation for each drug product; if female subjects are recruited they should not be pregnant EMA, Canada, Chinese Taipei, Singapore/ASEAN, South Korea, USA, WHO: Subjects can belong to either sex Japan: no mention other than healthy adult subjects Mexico: use subjects of one sex to avoid gender-related pharmacokinetic differences Number of subjects Similarities All request a minimum of 12 subjects, with the exception of the jurisdictions listed below Differences China: 18-24 Japan: a sufficient number to show BE Mexico: 24 unless scientifically justified Genotyping or phenotyping Similarities All either (1) do not mention; or (2) recommend for safety or pharmacokinetic reasons Differences Brazil, Canada, Japan, Mexico, South Korea, USA: Not mentioned China, EMA, Singapore/ASEAN, WHO: Consider for safety or pharmacokinetic reasons Dose strength used in the in vivo studies Similarities All recommend that generally in vivo studies should be performed on the highest strength, unless reasons of safety justify use of a lower strength Differences Some jurisdictions specify which strength should be used for drugs with nonlinear PK over the clinical dosing range, as follows Australia: imposes the following restrictions on BE studies of generic drugs with non-linear or complex PK Only a drug product marketed in Australia is acceptable as the reference Once this criterion is met, follow the recommendations in the EMA Guidelines Canada, EMA: the strength to be used depends upon the type of nonlinearity and the underlying causes If the nonlinearity is characterized by greater than proportional increases in AUC with increasing dose, conduct the BE studies on at least the highest strength If the nonlinearity is characterized by less than proportional increases in AUC with increasing dose and results from saturable absorption, conduct the in vivo studies on the lowest strength If the nonlinearity is reflected as less than proportional increases in AUC with increasing dose due to limited solubility of the active pharmaceutical ingredient, conduct in vivo studies on two strengths Canada requests a fasting study on the lowest strength and a fasting and fed study on the highest strength EMA requests a fasting and fed study on one strength and a fasting or fed study (justified based on previous knowledge and PK) on a second strength; the second strength should be the one most sensitive to detect a difference between products USA: the strength to be used depends upon the type of nonlinearity If the nonlinearity is characterized by greater than proportional increases in AUC with increasing dose, conduct the BE studies on at least the highest therapeutic dose (38) If the nonlinearity is characterized by less than proportional increases in AUC with increasing dose and results from saturable absorption, conduct the in vivo studies on the lowest strength (39) WHO: Generally the marketed strength with the greatest sensitivity to BE assessment should be administered as a single unit Analytes to be measured in biological fluids Similarities All request Measuring and requiring the parent drug to meet BE limits unless the parent cannot be reliably measured; and Measuring and requiring the major metabolite(s) to meet BE limits when the parent cannot be reliably measured Differences Some provide additional reasons for measuring metabolites in biological fluids, and differ in recommending how test and reference metabolite concentrations should be statistically compared, as follows: Brazil: measure and perform BE testing on metabolites which are Formed primarily by presystemic metabolism; and Contribute meaningfully to safety and efficacy Canada: quantification of metabolite levels may sometimes be helpful; for example, to explain extreme values caused by metabolite changes within a subject EMA: using the metabolite as a surrogate for an active parent drug is expected to be accepted only in exceptional cases;
the applicant should present any available data supporting the view that The metabolite exposure reflects parent drug Metabolite formation is not saturated at therapeutic doses Japan: Major active metabolites may be measured instead of the unchanged active ingredient, if it is rational Singapore/ASEAN: With justification, BE determination can be based on metabolites when
The metabolite significantly contribute to the net activity; and The pharmacokinetic system is non-linear South Korea: measure and perform BE testing on active metabolites USA: perform summary statistics only and use as supportive data when metabolites are Formed primarily by presystemic metabolism; and Contribute meaningfully to safety and efficacy. WHO: measure and perform BE testing on metabolites when
The parent is a pro-drug; or The metabolites are formed primarily by presystemic metabolism and contribute meaningfully to safety and efficacy Add-on, group-sequential, adaptive designs Similarities Very few jurisdictions/organizations recommend these types of designs Group-sequential and adaptive designs are recommended when the proposed estimate of the within-subject variability has large uncertainty. In a group-sequential design The overall Type I error and stopping criteria are clearly defined prior to starting the study; and The analysis of the first stage is treated as an interim analysis and both analyses are conducted at adjusted significance levels In an adaptive design, the second state sample size is based on the estimated within-subject variance from the first stage "Add-on" or "additional" studies are recommended when the first (preceding) study fails to meet BE limits In an appropriately designed add-on or additional study, data from the preceding BE study and add-on or additional study may be combined for statistical analysis, provided that Only one add-on or additional study is conducted; The add-on or additional study uses the same protocol as the preceding study; There are no fundamental differences between the first (preceding) BE study and add-on study with respect to formulation, design, and subjects; and The number of subjects to be included in the add-on or additional study is restricted Differences Australia: the most conservative of the approaches proposed in the literature, the Bonferroni correction, should be applied.
This corresponds to the calculation of 95%, rather than 90%, confidence intervals Brazil, China, Chinese Taipei, Mexico, Singapore/ASEAN, WHO: do not mention/specify Canada will accept a two-stage group-sequential BE study, provided that the plan to use a two-stage approach and adjusted significance levels is pre-defined in the protocol Recommends that the same alpha of 0.0294 be used for both stages (40) parameters in a BE study are the area under the drug concentration versus time profile until the last sampling time (AUC 0−t ), the area under the drug concentration versus time profile extrapolated to infinity (AUC∞), C max , T max , the drug half-life (T 1/2 ) in the biological fluid assayed, and the drug elimination rate constant (k el ). All use noncompartmental analysis to calculate the above PK parameters. In addition, all perform ln transformation on AUC and C max , and use the two one-sided tests procedure (50), performed at the 5% level of significance, to determine if the 90% CI of the test/ reference AUC and C max GMRs meet BE limits. All require the 90% CI of the test/reference GMR to meet BE limits of 80-125% for AUC 0−t (there are differences in the number of decimal places used for the 90% CI calculations, as will be explained below). Chinese Taipei, Japan, South Korea, and the USA require AUC∞ to meet BE limits. All recommend BE study design modifications for long T 1/2 drugs. Interestingly, only Brazil formally defines a "long elimination T 1/2 " as greater than 24 h. All permit truncation of AUC, although the truncation time varies somewhat from jurisdiction to jurisdiction. In addition, all note that a parallel study design may be considered for long T 1/2 drugs.
The jurisdictions and organizations vary in methods for statistically comparing test and reference C max . Canada requires the C max GMR (or "point estimate") to fall within 80-125%. All others impose BE limits on the 90% CI of the test/reference C max GMRs, although they vary in how the C max BE limits are set. Brazil, the EMA, Japan, Mexico, and South Korea require C max to meet BE limits of 80-125%. China uses limits of 70-143%. Chinese Taipei, Singapore/ASEAN, and the WHO specify that ordinarily, C max should meet limits of 80-125%, but when safety and efficacy concerns are justified, 75-133% may be considered with prior approval.
For steady-state BE studies, all require the 90% CIs of the test/reference GMRs to meet BE limits of 80-125% for AUC τ (AUC over the dosing interval). For C maxSS (C max at steady state), all require the 90% CIs of the test/reference GMRs to meet BE limits of 80-125%, with the exception of Canada, which requires that the GMR for C maxSS fall within 80-125% (as is required for C max ). In addition, all request noncompartmental calculation of T maxSS (T max at steady state), C minSS (trough drug concentrations at steady state), C avgSS (average steady-state drug concentrations), and percent fluctuation With respect to the number of decimal places considered in the BE statistical calculations, Brazil, China, Chinese Taipei, Japan, Mexico, Singapore/ASEAN, South Korea, and the WHO specify that the limits are 80-125%; Canada specifies 80.0-125.0%; the EMA and USA specify 80.00-125.00%.
Most jurisdictions and organizations evaluate T max if it is determined that this parameter is clinically relevant. They differ in how T max is evaluated in such circumstances. Brazil, China, Japan, Singapore/ASEAN, South Korea, and the WHO apply nonparametric analysis to statistically compare test and reference T max . The EMA and USA (51) state that the regulators will evaluate whether differences between test and reference T max values are clinically significant.
Highly Variable Drugs
HV drugs are defined as drugs in which the withinsubject variability (% CV) in one or more of the BE measures (AUC, C max ) is 30% or greater (52, 53) . Determining BE of HV drugs is challenging because, due to the high variability, it may be necessary to enroll large numbers of subjects to provide adequate power in order that a two-way study of two BE products will be acceptable (54) .
As shown in Table VI , jurisdictions/organizations use a variety of approaches to reduce the number of subjects needed for an acceptable study of two bioequivalent HV drugs. Several permit widening BE limits for C max if previously established in the study protocol and if scientifically justified. As previously mentioned, Japan, Singapore/ ASEAN, and the WHO suggest using a steady-state BE study design to reduce variability. Japan also recommends using studies with stable isotopes for HV drugs that may require large sample sizes in the BE studies. The EMA and USA recommend a reference-scaled average BE (RSABE) approach. In the RSABE approach, the reference product is administered twice in the study (either a three-or four-way design is acceptable), and the acceptance limits scale based on Canada (41), USA: Will accept a two-stage adaptive design BE study, provided that the intent to use the approach is predefined in the protocol EMA: Will accept two-stage group-sequential design BE studies, provided that the plan to use a two-stage approach and adjusted significance levels is predefined in the protocol Japan will accept add-on studies, provided that Not less than half the number of subjects in the initial study can be added-on The "study" is added to the statistical model as a source of variation South Korea will accept an additional trial; provided that
The additional trial uses at least 12 subjects per group The ratio of the mean square error from the ANOVAs of the preceding BE study and the additional trial should be smaller than the top 5% of an F-distribution with a corresponding degree of freedom; and The protocol should clearly state that additional trials were conducted. USA: will accept two-stage group-sequential design (40-43) BE studies, provided that the plan to use a two-stage approach and adjusted significance levels is predefined in the protocol the within-subject variability of the reference product. Both the EMA and USA impose a GMR constraint when using RSABE for HV drugs. As shown in Table VI , aside from the above similarities, the EMA and USA implement RSABE in different ways. In addition, the EMA only permits RSABE to be used for C max , whereas the USA will accept RSABE for both AUC and C max . Australia will consider using the EMA RSABE approach for BE studies of HV drugs provided that (1) the drug has highly variable PK due to incomplete or variable absorption or substantial (>40%) first-pass metabolism and (2) the reference product is one marketed in Australia. Finally, Canada states that there is no compelling need for a distinct category of HV drugs.
Narrow Therapeutic Index Drugs
NTI drug products are generally defined as those products containing certain drug substances subject to therapeutic drug concentration or pharmacodynamic monitoring and/or where product labeling indicates a narrow therapeutic range designation (56) . Other terminologies commonly used to refer to drugs with a narrow therapeutic index are "critical dose drugs" (57) and "narrow therapeutic range (NTR) drugs" (11, 58) . Different regulatory agencies use the terms "narrow therapeutic index," "narrow therapeutic range," and "critical dose" to designate drugs for which there is a narrowly defined plasma concentration range between risk and benefit. At present, the definitions of these three terms are basically the same across various regulatory agencies. The term "narrow therapeutic index" drugs or "NTI" drugs will be used throughout the remainder of this article; however, it is interchangeable with the terms "narrow therapeutic range" drugs and "critical dose" drugs.
The jurisdictions and organizations differ in recommendations of how to design and evaluate BE studies of generic NTI drugs. As shown in Table VII , Australia, Canada, China, Singapore/ASEAN, EMA, Japan, South Korea, Switzerland, and the WHO use more stringent acceptance limits for NTI Table V . Similarities and Differences in PK Parameter Determination and BE Statistics Single-dose fasting and fed BE studies Similarities All Use noncompartmental analysis to determine AUC 0−t , AUC∞, C max , and T max , T 1/2 , and k el for single-dose studies Perform log-transformation on AUC and C max Calculate test/reference GMRs for AUC and C max Use analysis of variance (ANOVA) and the two one-sided tests procedure, performed at the 5% level of significance, to determine if the 90% CIs of the test/reference GMRs meet BE limits Require AUC 0-t to meet 80-125% limits Differences Chinese Taipei, Japan, Singapore/ASEAN, South Korea, USA: 80-125% limits for AUC∞ Brazil, EMA, Japan, Mexico, South Korea, USA: 80-125% limits for C max Canada: the test/reference GMR for C max should fall within 80-125% China: 70-143% limits for C max Chinese Taipei, Singapore/ASEAN, WHO: for C max , ordinarily, 80-125% limits should be applied, but 75-133% limits may be considered with prior approval when safety and efficacy concerns are justified Japan, South Korea: products that do not meet BE acceptance limits may still be deemed bioequivalent provided that all of the following three criteria are met 1. The total sample size of the initial study is not <20 2. The GMRs for AUC and C max are within 0.9 to 1.11 3. In vitro dissolution behavior of the test and reference products is deemed to be the same under all conditions tested Long half-life drugs Similarities All permit truncation of AUC, to replace AUC Brazil, China, Japan, Singapore/ASEAN, South Korea, WHO: nonparametric analysis applied to non-transformed data, only if T max is judged to be clinically relevant South Korea: limits should be 80-125% Brazil, Japan, China, Singapore/ASEAN, WHO: limits should be a clinically determined range Canada: for drugs for which an early time of onset of action is important for therapeutic effects, the relative mean area under the curve to reference product T max (AUC TmaxRef ) should meet limits of 80-125% inclusive Chinese Taipei: not mentioned/specified EMA: if rapid release is claimed to be clinically relevant and of importance for onset of action or related to adverse events, there should be no apparent difference in T max and its variability between test and reference products USA: if differences in T max are judged to be clinically relevant, this may provide evidence that the test and reference products are not therapeutically equivalent (49) drugs. In Brazil, Chinese Taipei, and Mexico, BE limits for NTI drugs are not different from those for other drugs. The USA recently began to recommend a more stringent acceptance limit for some NTI drugs. Canada and Japan refer to NTI drugs as critical dose drugs and NTR drugs, respectively; both provide definitions in their respective guidelines (see Table VII ). The EMA concludes that it is not possible to define a set of criteria to categorize drugs as NTI and recommends deciding on a caseby-case basis. The USA recently proposed a RSABE approach for these products (60) (61) (62) . A RSABE approach should have the effect of narrowing the BE limits for NTI drugs. As BE acceptance limits scale based on the variability of the reference drug, and most NTI drugs have low withinsubject variability, use of reference scaling will in effect narrow the BE limit acceptance range As NTI drugs generally have low within-subject variability, such an approach will effectively narrow the BE limits. The USA also proposed narrowing the assayed potency specifications for the finished products; this latter approach is already in effect for levothyroxine tablets (63) . Table VIII shows similarities and differences in the biowaiver process. All permit the waiving of BE study requirements for products for which BE is self-evident. This includes solutions for parenteral, oral, or local use. There are If the generic drug has highly variable PK due to incomplete or variable absorption or substantial (>40%) first-pass metabolism, then the reference product must be one marketed in Australia If this criterion is met then follow the EMA recommendations for HVD BE studies Brazil: a wider BE acceptance limit may be applied to C max if previously established in the study protocol and if scientifically justified Chinese Taipei, South Korea: do not specify/mention Canada: no compelling need for a distinct category of HV drugs Singapore/ASEAN, WHO: one of the following approaches can be used:
Conditions Under Which Biowaivers may be Granted
In rare cases, a wider BE limit acceptance range may be applied to AUC and C max , if based on sound clinical justification A steady-state BE study can be conducted to reduce variability EMA: a RSABE approach may be applied to C max only. A brief summary of study design and acceptance criteria is as follows:
The reference product should be administered at least twice to determine within-subject variability Either a 3-or 4-period replicate design study is acceptable BE limits are scaled to the within subject variability of the reference product The C max GMR in the study should fall within 0.80- Japan: one of the following approaches may be used to reduce variability: For drugs with a wide therapeutic index, it may be appropriate to set BE limits wider than 80-125% for C max A steady-state BE study A study with stable isotope USA: a RSABE approach may be applied to AUC and C max (55) . A brief summary of study design and acceptance criteria is as follows:
The reference product should be administered at least twice to determine within-subject variability Either a 3-or 4-period replicate design study is acceptable; The AUC and C max GMRs in the study should fall within 0.80 to 1.25 BE limits are scaled to the within subject variability of the reference product, but not until the within-subject standard deviation of the reference product (s WR ) is ≥ 0.294; and A 95% upper confidence bound for (μ T −μ R ) 2 −θs WR 2 must be ≤0, where
generally additional criteria to be met before a biowaiver can be granted. Test and reference solutions intended for parenteral use should have the same active and inactive ingredients in the same amounts; generic solutions intended for oral or topical use should not contain excipients that could potentially cause differences in drug substance absorption. All will consider granting biowaivers for non-biostudy strengths of solid dosage forms, provided that certain requirements are met [proportional similarity across strengths; acceptable in vitro dissolution or in vitro drug release from the formulation; acceptable BE study on the bio-study strength(s)]. The USA does not grant biowaivers for MR products, but may deem non-biostudy strengths BE to corresponding strengths subject to certain criteria (64) . This policy applies to all MR dosage forms, including but not limited to delayed-release tablets and capsules, extendedrelease tablets, transdermal products, injectable suspensions, and injectable implants.
Use of the Biopharmaceutics Classification System to Grant Biowaivers
The BCS is a scientific framework for classifying drug substances based on their aqueous solubility and intestinal Generic NTI drugs must be compared to a reference drug product marketed in Australia If this criterion is met, then follow the EMA Guidelines with respect to other restrictions on BE studies of generic NTI drugs Brazil, Chinese Taipei, Mexico: do not specify/mention Canada: recommends the following for critical-dose drugs:
Provides a list Defines critical dose drugs as those drugs where comparatively small differences in dose or concentration lead to dose and concentration dependent, serious therapeutic failures, and/or serious adverse drug reactions, which may be persistent, irreversible, slowly reversible, or life threatening, which could result in inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability or incapacity, or death For critical-dose drugs, the 90% CI for AUC should be within 90.0-112.0 inclusive For critical-dose drugs, 90% CI for C max should be within 80.0-125.0 inclusive China, Singapore/ASEAN, WHO: in the case of an especially narrow therapeutic range, the BE limits may need to be tightened based on clinical justification EMA: recommends the following for NTI drugs:
In specific cases of NTI drugs, the acceptance interval for AUC should be tightened to 90.00-111.11%. Where C max is of particular importance for safety, efficacy, or drug level for monitoring the 90.00-111.11% acceptance interval should also be applied for this parameter It is not possible to define a set of criteria to categorize drugs as NTI Therefore, it must be decided on a case-by-case basis if an active substance is NTI based on clinical considerations Japan: recommends the following for NTR drugs:
Provides a list Defines NTR drugs as those having a less than twofold difference in the minimum toxic concentrations and minimum effective concentrations in the blood For NTI drugs, the acceptance interval for AUC and C max should be tightened to 90.00-111.11% (59) Imposes more stringent BE requirements for certain types of postapproval manufacturing process/site, or formulation changes South Korea: Recommends the following for NTI drugs Provides a list BCS biowaivers cannot be applied to NTI drugs Imposes more stringent types of BE requirements for certain types of postapproval manufacturing process/site, or formulation changes USA: current Guidance for Industry recommends that BE limits of 80-125% be applied to AUC and C max for NTI drugs BCS biowaivers cannot be applied to NTI drugs; and More stringent types of BE requirements are imposed on certain types of postapproval manufacturing process/site, or formulation changes In 2011, FDA presented a proposal on BE requirements for generic NTI drugs before its Advisory Committee; the Committee agreed with the proposal summarized below, which is still under development Develop a regulatory definition of NTI and post for notice and comment Require assayed potency specifications of 95-105% Use RSABE to scale the BE limits to the within-subject variability of the reference product, in cases where within-subject variability <20% If within-subject variability ≥20%, then use BE limits of 80-125% Develop statistical methods to assure that within-subject variability of generic product does not exceed that of reference product Post these recommendations for NTI drugs as Specific Products Bioequivalence Guidance for Industry on a case-by-case basis permeability (65) . When combined with the dissolution of the drug product, the BCS takes into account three major factors that govern the rate and extent of drug absorption from IR solid oral dosage forms; these factors are dissolution, solubility, and intestinal permeability. According to the BCS, drug substances are classified as follows: Within the BCS framework, when certain criteria are met, the BCS can be used as a drug development tool to justify the granting of biowaivers.
Currently, Australia, the EMA, Switzerland, and the WHO (66) will consider granting biowaivers for class I and III drugs. Canada recently issued a draft guidance for industry proposing criteria to be met for the granting of class I and III biowaivers (67) . South Korea and the USA will consider granting biowaivers for class I drugs. Regarding Singapore and China, the ASEAN Consultative Committee for Standards and Quality primarily considers the BCS criteria when evaluating applications for IR solid oral dosage forms, whereas China will consider granting BCS biowaivers for class I drugs undergoing postapproval changes (68) . All jurisdictions and organizations that consider granting BCS biowaivers stipulate that such biowaivers are not applicable to NTI drugs.
The WHO, under the PQP, which provides a stringent regulatory function for medicines, posted a supplementary guidance document on BCS biowaivers; this is the document currently used to evaluate drug products (66). The WHO also posts a general guidance on the topic of BCS-based biowaivers (35) . The general guidance provides information on the WHO position on BCS biowaivers and may be used as a guide for national regulatory authorities developing positions on this subject.
Japan maintains that formulation and manufacturing, rather than solubility and permeability, are indicative of bioequivalence (68) . In addition, Japan notes that dissolution testing is already extensively applied in drug regulatory submissions, and that since permeability is not known for many drugs, it is difficult to use BCS to establish regulatory bioequivalence.
For the jurisdictions and organizations that formally implement the BCS, Table IX shows what types of data should be submitted to support class I and III biowaivers.
CONCLUSION
BE studies are an important part of the generic drug approval process throughout the world. This review focused on the BE study requirements and regulatory specifications among a number of worldwide jurisdictions and organizations. Although there are important differences in BE approaches throughout the various regulatory agencies investigated in this article, we observed that, in general, there are many more similarities. This is particularly the case with respect to general BE study design, methods of calculating key PK parameters, statistical analysis methods used to verify BE, and criteria necessary for the granting of biowaivers. Identifying the existence of commonalities underlying regulatory evaluation of BE throughout the world is an important first step in working toward global harmonization and convergence of generic drug development. 
